ARSD

Across TCGA pan-cancer cohorts, ARSD Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ARSD data layer compared with 23 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher ARSD Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ARSD expression acts as an unfavorable survival marker.

KIRC, HNSC, and STAD are the cancer types where ARSD Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	DFS	Median	All	0.133	0.796	<.001	24	view →
HNSC	DFS	Median	All	0.122	0.712	<.001	24	view →
STAD	OS	Median	II,III,IV	0.141	0.565	.013	9	view →
COAD	OS	Median	All	0.539	0.805	.032	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ARSD–KIRC (DFS)

Open the KIRC breakdown →